Abstract
Background Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) fixed-dose combination (FTC/TDF) is generally well-tolerated, although treatment-related adverse events have been reported. Methods We report two cases of persons using FTC/TDF PrEP who had acute neuralgia in a Chinese PrEP demonstration trial. Results Neurological symptoms subsided upon treatment discontinuation. Symptoms were reported as similar to one case’s previous experiences with dolutegravir (DTG) + FTC + tenofovir alafenamide (TAF) (for PEP), leading to permanent discontinuation of PrEP. Conclusion Acute facial neuralgia appears to be a rare idiosyncratic adverse event to FTC/TDF.
Reference13 articles.
1. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.;Lancet Infect Dis,2014
2. On-demand oral pre-exposure prophylaxis with tenofovir/emtricitabine: what every clinician needs to know.;J Gen Intern Med,2020
3. Centers for Disease Control and Prevention. How effective is PrEP? 2022. Available at [cited 26 October 2023]
4. World Health Organization. Global state of PrEP; 2022. Available at [cited 28 October 2022]
5. Gilead Sciences. Science and medicine; 2023. Available at [cited 20 June 2023]